<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        36-5015-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DEVARIN 10MG ORODISPERSIBLE TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VARDENAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Orodispersible tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        53.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LABORATORIOS CINFA SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE09 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Devarin ODT contains vardenafil, a member of a class of medicines called phosphodiesterase type<br />5 inhibitors. They are used for the treatment of erectile dysfunction in adult men, a condition<br />which implies difficulties in getting or keeping an erection.<br />At least one in ten men has trouble getting or keeping an erection at some time. There may be<br />physical or psychological causes, or a mixture of both. Whatever the cause is, due to muscle and<br />blood vessel changes not enough blood stays in the penis to make it hard and keep it hard.<br />Devarin ODT will only work when you are sexually stimulated. It reduces the action of the natural<br />chemical in your body which makes erections go away. Devarin ODT allows an erection to last<br />long enough for you to satisfactorily complete sexual activity.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Devarin ODT<br />- If you are allergic to vardenafil or any of the other ingredients of this medicine (listed in<br />section 6). Signs of an allergic reaction include a rash, itching, swollen face or lips and shortness<br />of breath.<br />- If you are taking medicines containing nitrates, such as glycerol trinitrate for angina, or<br />nitric oxide donors, such as amyl nitrite. Taking these medicines with vardenafil<br />orodispersible could seriously affect your blood pressure.<br />- If you are taking ritonavir or indinavir, medicines used to treat human immunodeficiency<br />virus (HIV) infections.<br />- If you are over 75 years of age and are taking ketoconazole or itraconazole, anti-fungal<br />medicines.<br />- If you have a severe heart or liver problem.<br />- If you are having kidney dialysis.<br />- If you have recently had a stroke or heart attack.<br />- If you have or have had low blood pressure.<br />- If your family has a history of degenerative eye diseases (such as retinitis pigmentosa).<br />- If you have ever had a condition involving loss of vision due to damage to the optic<br />nerve from insufficient blood supply known as non-arteritic ischaemic optic neuropathy<br />(NAION).<br />- If you are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e.<br />high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e.<br />high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as vardenafil<br />have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat<br />or are unsure tell your doctor.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Devarin ODT.<br />Take special care with vardenafil orodispersible tablets<br />- If you have heart trouble. It may be risky for you to have sex.<br />- If you suffer from irregular heart beat (cardiac arrhythmia) or inherited heart diseases<br />affecting your electrocardiogram.<br />- If you have a physical condition affecting the shape of the penis. This includes<br />conditions called angulation, Peyronie&rsquo;s disease and cavernosal fibrosis.<br />- If you have an illness that can cause erections which won&rsquo;t go away (priapism). These<br />include sickle cell disease, multiple myeloma and leukaemia.<br />- If you have stomach ulcers (also called gastric or peptic ulcers).<br />- If you have a bleeding disorder (such as haemophilia).<br />- If you are using any other treatments for erection difficulties, including vardenafil filmcoated<br />tablets (see section Other medicines and Devarin ODT).<br />- If you experience sudden decrease or loss of vision, stop taking Devarin ODT and<br />contact your doctor immediately.<br />Children and adolescents<br />Vardenafil orodispersible is not intended for use by children or adolescents under 18.<br />Other medicines and Devarin ODT<br />Please tell your doctor or pharmacist if you are using, have recently used or might use any other<br />medicines, including medicines obtained without a prescription.<br />Some medicines may cause problems, especially these:<br />&bull; Nitrates, medicines for angina, or nitric oxide donors, such as amyl nitrite. Taking these<br />medicines with vardenafil orodispersible tablets could seriously affect your blood pressure. Talk<br />to a doctor without taking Devarin ODT.<br />&bull; Medicine for the treatment of arrhythmias, such as quinidine, procainamide, amiodarone<br />or sotalol.<br />&bull; Ritonavir or indinavir, medicines for HIV. Talk to a doctor without taking Devarin ODT.<br />&bull; Ketoconazole or itraconazole, anti-fungal medicines.<br />&bull; Erythromycin or clarithromycin, macrolide antibiotics.<br />&bull; Alpha-blockers, a type of medicine used to treat high blood pressure and enlargement of<br />the prostate (as benign prostatic hyperplasia).<br />&bull; Riociguat.<br />Do not use vardenafil orodispersible tablets combined with any other treatment for erectile<br />dysfunction, including vardenafil film-coated tablets.<br />Devarin ODT with food, drink and alcohol<br />- You can take Devarin ODT with or without food but do not take this medicine with any<br />liquid.<br />- Don&rsquo;t drink grapefruit juice when you use Devarin ODT. It can interfere with the usual<br />effect of the medicine.<br />- Alcoholic drink can make erection difficulties worse.<br />Pregnancy and breast-feeding<br />Vardenafil orodispersible is not for use by women.<br />Driving and using machines<br />Vardenafil might make some people feel dizzy or affect their vision. If you feel dizzy, or if your<br />vision is affected after taking vardenafil orodispersible don&rsquo;t drive or operate any tools or<br />machines.<br />Devarin ODT contains Aspartame and lactose monohydrate.<br />- Aspartame is a source of phenylalanine, and may be harmful for people with a disorder<br />called phenylketonuria.<br />- Lactose monohydrate: If you have been told by your doctor that you have an intolerance to<br />some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or<br />pharmacist if you are not sure. The recommended dose is 10 mg.<br />Take a Devarin ODT tablet about 25 to 60 minutes before sexual activity. With sexual<br />stimulation you may achieve an erection anywhere from 25 minutes up to four to five hours<br />after taking Devarin ODT.<br />- Do not remove the orodispersible tablet from the blister until you are going to take it..<br />With dry hands press gently to release the tablet on your hand. Do not crush the tablet.<br />- Place the entire orodispersible tablet in the mouth, on the tongue, where it will dissolve in<br />seconds, then swallow with saliva. The orodispersible tablet must be taken without any liquid.<br />Do not take Devarin ODT orodispersible tablets with any other forms of vardenafil.<br />Do not take Devarin ODT more than once a day.<br />Tell your doctor if you think Devarin ODT is too strong or too weak. He or she may suggest a<br />switch to an alternative vardenafil formulation with a different dose, depending on how well it<br />works for you.<br />If you take more Devarin ODT than you should<br />Men who take too much Devarin ODT may experience more side effects or may get severe back<br />pain. If you take more Devarin ODT than you should, tell your doctor.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most<br />of the effects are mild or moderate.<br />Partial, sudden, temporary or permanent decrease or loss of vision in one or both eyes has been<br />experienced by patients. Stop taking Devarin ODT and contact your doctor immediately.<br />Sudden decrease or loss of hearing has been reported.<br />The chance of having a side effect is described by the following categories:<br />Very common:<br />may affect more than 1 in 10 users<br />- Headache<br />Common:<br />may affect up to 1 in 10 users<br />- Dizziness<br />- Flushing<br />- Blocked or runny nose<br />- Indigestion<br />Uncommon:<br />may affect up to 1 in 100 users<br />- Swelling of skin and mucous tissue including swollen face, lips or throat<br />- Sleep disorder<br />- Numbness and impaired perception of touch<br />- Sleepiness<br />- Effects on vision, redness of the eye, effects on colour vision, eye pain and discomfort,<br />light sensitivity<br />- Ringing in the ears, vertigo<br />- Fast heart beat or pounding heart<br />- Breathlessness<br />- Stuffy nose<br />- Acid reflux, gastritis, abdominal pain, diarrhoea, vomiting; feeling sick (nausea), dry mouth<br />- Raised levels of liver enzymes in your blood<br />- Rash, reddened skin<br />- Back or muscle pain, increase in blood of a muscle enzyme (creatine phosphokinase),<br />muscle stiffness<br />- Prolonged erections<br />- Malaise<br />Rare:<br />may affect up to 1 in 1,000 users<br />- Inflammation of the eyes (conjunctivitis)<br />- Allergic reaction<br />- Anxiety<br />- Fainting<br />- Amnesia<br />- Seizure<br />- Increased pressure in the eye (glaucoma), lacrimation increased<br />- Effects on the heart (such as heart attack, altered heart beat or angina)<br />- High or low blood pressure<br />- Nose bleed<br />- Effect on results of blood tests to check liver function<br />- Sensitivity of the skin to sun light<br />- Painful erections<br />- Chest pain<br />Very rare or not known:<br />may affect less than 1 in 10,000 users or frequency cannot be estimated from the available data<br />- Blood in the urine (Haematuria)<br />- Penile bleeding (Penile Haemorrhage)<br />- Presence of blood in the semen (Haematospermia)<br />Reporting of side effects<br />If you get any side effects, talk to your doctor. This includes any possible side effects not listed in<br />this leaflet. You can also report side effects directly (see details below). By reporting side effects,<br />you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The<br />expiry date refers to the last day of that month.<br />Do not store above 30&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how<br />to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Devarin ODT contains<br />- The active substance is vardenafil.<br />Each orodispersible tablet contains: vardenafil 10 mg (vardenafil HCl trihydrate 11.85 mg).<br />The other ingredients of the tablets are:<br />Lactose monohydrate, calcium silicate, hydroxypropyl cellulose, crospovidone, aspartame, mint<br />flavour, aniseed flavour, colloidal silicon dioxide and magnesium stearate.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Devarin ODT 10 mg are biconvex, cylindrical, white to off white, non-scored with the code
“VB” on one side.
Devarin ODT is supplied in packages containing 4 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer<br />LABORATORIOS CINFA, S.A.<br />OlazChipi,10. Pol&iacute;gono Industrial Areta,<br />31620 Huarte-Pamplona (Navarra) &ndash; Spain<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 09/2018.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ديفارين على مادة فاردينافيل، التي تنتمي لفئة من الأدوية تُعرف باسم مثبطات إنزيم فُسْفُودايسْتِريز من النوع الخامس. وتُستخدم لعلاج خلل القدرة على الانتصاب لدى الذكور البالغين، وهي حالة مرضية تؤدي إلى صعوبة في حدوث الانتصاب أو الحفاظ عليه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعاني رجل واحد على الأقل من كل عشرة رجال صعوبة في الانتصاب أو الحفاظ عليه في بعض الأحيان. والسبب قد يكون بدني أو نفسي أو مزيج منهما. ومهما كان السبب، فنتيجة لحدوث تغيرات في العضلات والأوعية الدموية لا يحتفظ العضو الذكري بكمية من الدم تكفي لجعله صلباً أو محافظاً على صلابته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل ديفارين فقط عندما يكون الجسم في حالة استثارة جنسية. فهو يقلل من مفعول المواد الكيميائية الطبيعية داخل الجسم التي تساعد في زوال الانتصاب سريعاً. يساعد ديفارين في جعل الانتصاب يدوم للمدة الكافية لإتمام النشاط الجنسي بشكل مُرضي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناول ديفارين</strong><strong> </strong><strong>في الحالات التالية:</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك حساسية من مادة فاردينافيل أو أي من مكونات الدواء الأخرى (المدرجة في قسم 6). وتتضمن علامات التفاعلات التحسسية: الطفح الجلدي والحكة وتورم الوجه أو الشفاه وضيق في التنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية تحتوي على نيترات، مثل ثلاثي نيترات الجليسرول المُستخدم لعلاج الذبحة الصدرية أو معطيات أكسيد النيتريك مثل نيتريت الأميل. تناول هذه الأدوية مع ديفارين قد يؤثر بشكل خطير في ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تتناول ريتونافير أو إندينافير، وهي أدوية تُستخدم لعلاج فيروس نقص المناعة البشري (HIV).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كان عمرك يزيد على 75 عاماً وكنت تتناول&nbsp; كيتاكونازول أو إتراكونازول، وهي أدوية مضادة للفطريات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تعاني مشكلة خطيرة في القلب أو الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تخضع لعملية الغسيل الكلوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت مؤخراً بسكتة دماغية أو أزمة قلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت مصاباً أو أصبت من قبل بانخفاض في ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كان لدى عائلتك تاريخ من أمراض العيون التنكسية (مثل التهاب الشبكية الصباغي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت مُسبقاً بحالة مرضية تسببت في فقدان الرؤية نتيجة لتلف في العصب البصري نتيجة نقص كمية الدم الواصلة له (إمداد الدم) وهي حالة تُعرف باسم الاعتلال العصبي البصري الأمامي لنقص التروية (NAION).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تتناول عقار ريوسيجوات. يُستخدم هذا العقار لعلاج ارتفاع ضغط الدم في الشريان الرئوي (أي ارتفاع ضغط الدم في الرئتين) وارتفاع ضغط الدم الرئوي الانسدادي التجلطي المزمن (أي ارتفاع ضغط الدم في الرئتين نتيجة لحدوث تجلطات دموية). مثبطات إنزيم فُسْفُودايسْتِريز النوع الخامس، مثل فاردينافيل، أظهرت زيادة في تأثير هذه الأدوية في خفض ضغط الدم. إذا كنت تتناول عقار ريوسيجوات أو كنت غير متأكد فأخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول إكس<sub>- </sub>بيرت دي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخَّ الحذر الشديد عند تناول إكس<sub>- </sub>بيرت دي</strong></p><p dir="RTL">-&nbsp; إذا كنت مصاباً بمشكلة في القلب. فقد تتعرض حياتك للخطر إذا مارست الجنس.</p><p dir="RTL">-&nbsp; إذا كنت تعاني عدم انتظام ضربات القلب أو أمراض قلبية وراثية تؤثر في مخطط رسم القلب.</p><p dir="RTL">-&nbsp; إذا كنت مصاباً بمرض بدني يؤثر في شكل القضيب. وتشمل حالات مرضية تُعرف باسم التزوي وداء بيروني والتليف الكهفي.</p><p dir="RTL">-&nbsp; إذا كنت مصاباً باعتلال يسبب حالات انتصاب لا تزول (القساح). وتشمل أنيميا خلايا الدم المنجلية والورم النخاعي المتعدد وسرطان الدم.</p><p dir="RTL">-&nbsp; إذا كنت مصاباً بقرح في المعدة (تُعرف أيضاً باسم قرح معدية أو قرح هضمية).</p><p dir="RTL">-&nbsp; إذا كنت مصاباً باضطراب نزيفي (مثل سيولة الدم).</p><p dir="RTL">-&nbsp; إذا كنت تستخدم أي أدوية أخرى لعلاج صعوبة الانتصاب، ومنها أقراص فاردينافيل المغلفة (انظر القسم: التفاعلات مع الأدوية الأخرى).</p><p dir="RTL">-&nbsp; إذا كنت تعاني ضعفاً أو فقداناً مفاجئاً للرؤية، توقف عن تناول ديفارين واتصل بطبيك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">ديفارين غير مخصص للاستخدام من قِبل الأطفال أو المراهقين الذين لم يبلغوا 18 عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التفاعلات مع الأدوية الأخرى:</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">بعض الأدوية قد تؤدي إلى حدوث مشكلات، وخاصةً الأدوية التالية:</p><p dir="RTL">-&nbsp; النيترات أو الأدوية المخصصة لعلاج الذبحة الصدرية أو معطيات أكسيد النيتريك، مثل نيتريت الأميل. تناول هذه الأدوية مع أقراص فاردينافيل القابلة للذوبان بالفم<strong> </strong>قد يؤثر بشكل خطير في ضغط الدم. تحدث مع طبيبك قبل تناول إكس<sub>- </sub>بيرت دي.</p><p dir="RTL">-&nbsp; الأدوية المستخدمة لعلاج عدم انتظام ضربات القلب، مثل كوینیدین أو بركاييناميد أو أميودارون أو سوتالول.</p><p dir="RTL">-&nbsp; ريتونافير أو إندينافير أو أدوية فيروس نقص المناعة البشري. تحدث مع طبيبك قبل تناول إكس<sub>- </sub>بيرت دي.</p><p dir="RTL">-&nbsp; كيتوكونازول أو إيتراكونازول، وهي أدوية مضادة للفطريات.</p><p dir="RTL">-&nbsp; إریثرومایسین أو كلاريثروميسين، وهي مضادات حيوية ماركروليدية.</p><p dir="RTL">-&nbsp; حاصرات ألفا، نوع من الأدوية يُستخدم لعلاج ارتفاع ضغط الدم وتضخم البروستاتا (مثل تضخم البروستاتا الحميد).</p><p dir="RTL">-&nbsp; ريوسيجات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول أقراص ديفارين القابلة للذوبان بالفم في نفس الوقت مع أي دواء آخر يُستخدم لعلاج اعتلال الانتصاب، بما في ذلك أقراص فاردينافيل المغلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أقراص ديفارينمع الطعام والشراب والكحول:</strong></p><p dir="RTL">-&nbsp; يمكنك تناول أقراص ديفارين مع الطعام أو من دونه - ولكن لا تتناولها مع أي سوائل.</p><p dir="RTL">-&nbsp; لا تتناول عصير الجريب فروت عند استخدام إكس<sub>- </sub>بيرت دي. من الممكن أن يتداخل مع مفعول الدواء المعتاد.</p><p dir="RTL">-&nbsp; قد تؤدي المشروبات الكحولية &nbsp;إلى زيادة حالة صعوبة الانتصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">لا يُستخدم ديفارين من قِبل السيدات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">قد يصيب فاردينافيل بعض الأشخاص بالدوار وقد يؤثر في رؤيتهم. إذا شعرت بالدوار الشعور بالدوار أو تأثرت رؤيتك بعد تناول ديفارين فتجنب القيادة أو تشغيل الأدوات أو الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوى ديفارين</strong><strong> </strong><strong>على أسبرتام ومونوهيدرات اللاكتوز.</strong></p><p dir="RTL">-&nbsp; أسبرتام هو مصدر للفينيل ألانين وقد يتسبب في إصابة بعض الأشخاص باضطراب يُعرف بالبوال التخلفي.</p><p dir="RTL">-&nbsp; مونوهيدرات اللاكتوز: إذا أخبرك طبيبك بأنك تعاني حساسية من بعض أنواع السكر فاستشر طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً حسب وصف الطبيب. استشر الطبيب أو الصيدلي إذا لم تكن متأكداً. الجرعة الموصى بها هي 10 ملجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول قرص ديفارين قبل ممارسة النشاط الجنسي بمدة تتراوح بين 25 و60 دقيقة. مع حدوث إثارة جنسية قد يحدث انتصاب يدوم لمدة تتراوح بين 25 دقيقة أو أربع ساعات أو خمس ساعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp; لا تُخرج القرص القابل للذوبان بالفم من الشريط إلا عند تناوله. اضغط برفق على القرص بيديك الجافتين لإخراجه من الشريط. لا تطحن الأقراص.</p><p dir="RTL">-&nbsp; ضع القرص القابل للذوبان بالفم على اللسان كي يذوب خلال ثوانٍ وتبتلعه مع اللعاب. تؤخذ الأقراص القابلة للذوبان بالفم دون تناول &nbsp;أي سوائل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناول أقراص </strong><strong>ديفارين</strong><strong> </strong><strong>القابلة للذوبان بالفم </strong>مع أي أشكال أخرى من مادة فاردينافيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناول </strong><strong>ديفارين</strong><strong> </strong>أكثر من مرة واحدة يومياً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تعتقد أن مفعول ديفارين قوي جداً أو ضعيف جداً. قد يقترح الطبيب أو الطبيبة الانتقال لتناول تركيبة بديلة لفاردينافيل بجرعة مختلفة، بناءً على مدى تأثيره عليك.</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من </strong><strong>إكس<sub>- </sub>بيرت دي</strong></p><p dir="RTL">قد يُصاب الرجال الذين يتناولون جرعة زائدة من ديفارين بمزيد من الآثار الجانبية وقد يعانون ألماً شديداً في الظهر. إذا تناولت جرعة زائدة من ديفارين فأخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p>إذا كان لديك أي أسئلة أخرى عن طريقة استخدام هذا الدواء فاسأل الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">مثل كل الأدوية، قد يسبب هذا الدواء آثاراً جانبية، ولكنها لا تظهر بالضرورة على كل من يتناوله. معظم الآثار الجانبية خفيفة أو متوسطة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعانى بعض المرضى ضعفاً أو فقداناً للرؤية بشكل جزئي أو مفاجئ أو مؤقت أو دائم في إحدى العينين أو كلتيهما. إذا ظهر عليك هذه الأعراض فتوقف عن تناول ديفارين واتصل بطبيبك على الفور.</p><p dir="RTL">تم الإبلاغ عن حدوث حالات ضعف أو فقدان مفاجئ لحاسة السمع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُصنف احتمال الإصابة بآثار جانبية في الفئات التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جداً:</strong></p><p dir="RTL">قد تؤثر في أكثر من شخص واحد من كل 10 أشخاص</p><p dir="RTL">- الصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة:</strong></p><p dir="RTL">قد تؤثر في شخص واحد من كل 10 أشخاص</p><p dir="RTL">-&nbsp; الدوار.</p><p dir="RTL">-&nbsp; احمرار الوجه.</p><p dir="RTL">-&nbsp; انسداد الأنف أو الرشح.</p><p dir="RTL">-&nbsp; عسر هضم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة:</strong></p><p dir="RTL">قد تؤثر في شخص واحد من كل 100 شخص</p><p dir="RTL">-&nbsp; تورم الجلد والأنسجة المخاطية بما في ذلك تورم الوجه أو الشفاه أو الحلق.</p><p dir="RTL">-&nbsp; اضطراب النوم.</p><p dir="RTL">-&nbsp; شعور بالتخدير واضطراب حاسة اللمس.</p><p dir="RTL">-&nbsp; الشعور بالنُعاس.</p><p dir="RTL">-&nbsp; تأثيرات في الرؤية: احمرار العين، خلل في رؤية الألوان، ألم أو شعور بعدم الراحة في العين، حساسية من الضوء.</p><p dir="RTL">- طنين في الأذن، دوار.</p><p dir="RTL">- ضربات قلب سريعة أو ضربات قلب عنيفة متتالية.</p><p dir="RTL">- صعوبة في التنفس.</p><p dir="RTL">- انسداد في الأنف.</p><p dir="RTL">- أمراض ارتجاع معدي مريئي، والتهاب المعدة، وألم في البطن، وإسهال، وقيء، والشعور بالإعياء (غثيان)، وجفاف الفم.</p><p dir="RTL">- ارتفاع مستويات إنزيمات الكبد في الدم.</p><p dir="RTL">- الطفح الجلدي، واحمرار الجلد.</p><p dir="RTL">- ألم في الظهر أو العضلات، ارتفاع مستويات إنزيم العضلات (كرياتينين فوسفوكاينيز) في الدم، تيبس في العضلات.</p><p dir="RTL">- حالات انتصاب لمدة طويلة.</p><p dir="RTL">- الإعياء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة:</strong></p><p dir="RTL">قد تؤثر في شخص واحد من كل 1,000 شخص</p><p dir="RTL">-&nbsp; التهاب العينين (التهاب الملتحمة).</p><p dir="RTL">-&nbsp; تفاعلات حساسية.</p><p dir="RTL">-&nbsp; الأرق.</p><p dir="RTL">-&nbsp; إغماء.</p><p dir="RTL">-&nbsp; فقدان الذاكرة.</p><p dir="RTL">-&nbsp; نوبات مرضية.</p><p dir="RTL">-&nbsp; زيادة في ضغط العين (مياه زرقاء)، وزيادة إفراز الدموع.</p><p dir="RTL">-&nbsp; تأثيرات في القلب (مثل أزمة قلبية، أو تغير نظم ضربات القلب، أو ذبحة).</p><p dir="RTL">-&nbsp; ارتفاع ضغط الدم أو انخفاضه.</p><p dir="RTL">-&nbsp; نزيف الأنف.</p><p dir="RTL">-&nbsp; تغير نتائج اختبارات الدم لفحص وظائف الكبد.</p><p dir="RTL">-&nbsp; حساسية الجلد من أشعة الشمس.</p><p dir="RTL">-&nbsp; حالات انتصاب مصحوبة بألم.</p><p dir="RTL">-&nbsp; ألم في الصدر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة جدا</strong><strong>ً</strong><strong> أو غير محددة المعدل:</strong></p><p dir="RTL">قد تؤثر في أقل من شخص واحد من كل 10,000 شخص أو لا يمكن تقدير معدل تكرارها من البيانات المتاحة</p><p dir="RTL">-&nbsp; دم في البول (بول دموي).</p><p dir="RTL">-&nbsp; نزف من القضيب.</p><p dir="RTL">-&nbsp; وجود دم في السائل المنوي.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن ظهور آثار جانبية</strong></p><p dir="RTL">إذا ظهر عليك أي أثار جانبية فتحدث إلى طبيبك. ويشمل هذا أي آثار جانبية محتملة غير واردة في هذه النشرة. يمكنك أيضاً الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). يمكنك المساهمة في تقديم المزيد من المعلومات المتعلقة بسلامة هذا الدواء وذلك بإبلاغنا عن ظهور آثار جانبية له.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن مرأى و متناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على العلبة بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تُحفظ في درجة حرارة تقل عن 30 ْم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي التخلص من أي أدوية عن طريق مياه الصرف أو النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستعملها؛ إذ تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحتوي </strong><strong>ديفارين</strong><strong> </strong><strong>على</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>المادة الفعالة هي فاردينافيل.</p><p dir="RTL">يحتوي كل قرص قابل للذوبان بالفم على: فاردينافيل 10 ملجم (فاردينافيل هيدروكلوريد ترايهيدرات 11.85 ملجم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى لهذه الأقراص هي:</p><p dir="RTL">مونوهيدرات اللاكتوز، وسيليكات الكالسيوم، وهيدروكسي بروبيل السيللوز، والكروسبوفيدون، والأسبرتام، ونكهة النعناع، ونكهة بذور اليانسون، وثاني أكسيد السيليكون الغروي، وستيارات الماغنسيوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الصيدلي لدواء </strong><strong>ديفارين</strong><strong> </strong><strong>ومحتويات العلبة</strong></p><p dir="RTL">ديفارين10 ملجم أقراص قابلة للذوبان بالفم، أسطوانية الشكل، محدبة الوجهين، ذات لون أبيض إلى أبيض مائل للصفرة، غير محززة من المنتصف ومحفور على أحد جانبيها الرمز &quot;VB&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوفر أقراص ديفارين في عبوات تحتوي على 4 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المُصنعة المالكة لحق التسويق:</strong></p><p dir="RTL">مختبرات سينفا، ش.م.</p><p dir="RTL">شارع أولاز شيبي، 10 منطقة بوليغنو الصناعية،</p><p dir="RTL">31620 أوارتي-بامبلونا (نافارا) - إسبانيا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أُجريت آخر مراجعة لهذه النشرة في ديسمبر 2017.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Devarin ODT 10 mg orodispersible tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each orodispersible tablet contains: vardenafil 10 mg (vardenafil HCl trihydrate 11.85 mg).
Excipients: 92.55 mg lactose monohydrate and 1.50 mg aspartame per orodispersible tablet.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Devarin ODT 10 mg are biconvex, cylindrical, white to off white, non-scored with the code
“VB” on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of erectile dysfunction in adult men. Erectile dysfunction is the inability to achieve<br />or maintain a penile erection sufficient for satisfactory sexual performance.<br />In order for Devarin ODT to be effective, sexual stimulation is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Devarin ODT 10 mg orodispersible tablets are not bioequivalent to Devarin 10 mg film-coated<br />tablets (see section 5.1). The maximum dose for Devarin ODT is 10 mg/day.<br />Use in adult men<br />Devarin ODT 10 mg orodispersible tablets are taken as needed approximately 25 to 60<br />minutes before sexual activity.<br />Special populations<br />Elderly (&ge;65 years old)<br />Dose adjustments are not required in elderly patients. However, an increase to a maximum<br />dose of vardenafil 20 mg film- coated tablets should be carefully considered depending on the<br />individual tolerability (see sections 4.4 and 4.8).<br />Hepatic impairment<br />Vardenafil orodispersible tablets are not indicated as a starting dose in patients with mild<br />hepatic impairment (Child- Pugh A).<br />Patients with mild hepatic impairment should start treatment with vardenafil 5 mg film-coated<br />tablets. Based on tolerability and efficacy, the dose may be increased to vardenafil 10<br />mg and 20 mg film-coated tablets, or vardenafil orodispersible tablets.<br />The maximum dose recommended in patients with moderate hepatic impairment (Child-Pugh<br />B) is vardenafil orodispersible 10 mg as film- coated tablets (see section 5.2).<br />Vardenafil orodispersible tablets are not for use in patients with moderate (Child-Pugh B) and<br />severe hepatic impairment (Child-Pugh C; see section 4.3).<br />Renal impairment<br />No dose adjustment is required in patients with mild to moderate renal impairment.<br />In patients with severe renal impairment (creatinine clearance &lt;30 ml/min) a starting dose of<br />vardenafil 5 mg film-coated tablets should be considered. Based on tolerability and efficacy,<br />the dose may be increased to vardenafil 10 mg and 20 mg film-coated tablets, or vardenafil<br />10 mg orodispersible tablets.<br />Vardenafil orodispersible is not for use in patients with end-stage renal failure (see section<br />4.3).<br />Paediatric population<br />Vardenafil orodispersible tablets are not indicated for individuals below 18 years of age. There<br />is no relevant indication for use of vardenafil orodispersible tablets in children and<br />adolescents.<br />Use in patients using other medicinal products Concomitant use of moderate or potent CYP<br />3A4 inhibitors<br />Vardenafil dose adjustment is necessary if moderate or potent CYP 3A4 inhibitors are given<br />concomitantly (see section 4.5).<br />Method of administration For oral use.<br />The orodispersible tablet should be placed in the mouth on the tongue, where it will rapidly<br />disintegrate, and then swallowed. Devarin ODT must be taken without liquid and immediately<br />upon release from the blister.<br />Devarin ODT can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
The co-administration of vardenafil with nitrates or nitric oxide donors (such as amyl nitrite)
in any form is contraindicated (see sections 4.5 and 5.1).
Vardenafil orodispersible is contraindicated in patients who have loss of vision in one eye
because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether
this episode was in connection or not with previous phosphodiesterase 5 (PDE5) inhibitor
exposure (see section 4.4).
Medicinal products for the treatment of erectile dysfunction should generally not be used in
men for whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders
such as unstable angina or severe cardiac failure [New York Heart Association III or IV]).
The safety of vardenafil has not been studied in the following sub-groups of patients and its
use is therefore contraindicated until further information is available:
- severe hepatic impairment (Child-Pugh C),
- end stage renal disease requiring dialysis,
- hypotension (blood pressure <90/50 mmHg),
- recent history of stroke or myocardial infarction (within the last 6 months),
- unstable angina, and
- known hereditary retinal degenerative disorders such as retinitis pigmentosa.
Concomitant use of vardenafil with the potent CYP3A4 inhibitors ketoconazole and
itraconazole (oral form) is contraindicated in men older than 75 years.
Concomitant use of vardenafil with HIV protease inhibitors such as ritonavir and indinavir is
contraindicated, as they are very potent inhibitors of CYP3A4 (see section 4.5).
The co-administration of PDE5 inhibitors, including vardenafil, with guanylate cyclase
stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic
hypotension (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A medical history and physical examination should be undertaken to diagnose erectile<br />dysfunction and determine potential underlying causes, before pharmacological treatment is<br />considered.<br />Prior to initiating any treatment for erectile dysfunction, physicians should consider the<br />cardiovascular status of their patients, since there is a degree of cardiac risk associated with<br />sexual activity (see section 4.3). Vardenafil has vasodilator properties, resulting in mild and<br />transient decreases in blood pressure (see section 5.1). Patients with left ventricular outflow<br />obstruction, e.g. aortic stenosis and idiopathic hypertrophic subaortic stenosis, can be sensitive<br />to the action of vasodilators including Type 5 phosphodiesterase inhibitors.<br />Medicinal products for the treatment of erectile dysfunction should be used with caution in<br />patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or<br />Peyronie&#39;s disease), or in patients who have conditions which may predispose them to<br />priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).<br />The safety and efficacy of combinations of vardenafil orodispersible tablets with vardenafil<br />film-coated tablets or other treatments for erectile dysfunction have not been studied.<br />Therefore the use of such combinations is not recommended.<br />Tolerability of the maximum dose of vardenafil 20 mg film-coated tablets may be lower in<br />elderly patients (&ge; 65 years old) (see sections 4.2 and 4.8).<br />Concomitant use of alpha-blockers<br />The concomitant use of alpha-blockers and vardenafil may lead to symptomatic hypotension<br />in some patients because both are vasodilators. Concomitant treatment with vardenafil should<br />only be initiated if the patient has been stabilised on his alpha-blocker therapy. In those<br />patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest<br />recommended starting dose of 5 mg film-coated tablets. Patients treated with alpha-blockers<br />should not use vardenafil 10 mg orodispersible tablets as a starting dose. Vardenafil may be<br />administered at any time with tamsulosin or with alfuzosin. With other alpha-blockers a time<br />separation of dose should be considered when vardenafil is prescribed concomitantly (see<br />section 4.5). In those patients already taking an optimised dose of vardenafil, alpha-blocker<br />therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be<br />associated with further lowering of blood pressure in patients taking vardenafil.<br />Concomitant use of CYP3A4 inhibitors<br />Concomitant use of vardenafil with potent CYP 3A4 inhibitors such as itraconazole and<br />ketoconazole (oral form) should be avoided as very high plasma concentrations of vardenafil<br />are reached if the medicinal products are combined (see sections 4.5 and 4.3).<br />Vardenafil dose adjustment might be necessary if moderate CYP 3A4 inhibitors such as<br />erythromycin and clarithromycin, are given concomitantly (see section 4.2 and 4.5).<br />Concomitant intake of grapefruit or grapefruit juice is expected to increase the plasma<br />concentrations of vardenafil. The combination should be avoided (see section 4.5).<br />Effect on QTc interval<br />Single oral doses of 10 mg and 80 mg of vardenafil have been shown to prolong the QTc<br />interval by a mean of 8 msec and 10 msec, respectively. And single doses of 10 mg vardenafil<br />co-administered concomitantly with 400 mg gatifloxacin, an active substance with comparable<br />QT effect, showed an additive QTc effect of 4 msec when compared to either active substance<br />alone. The clinical impact of these QT changes is unknown (see section 5.1).<br />The clinical relevance of this finding is unknown and cannot be generalised to all patients<br />under all circumstances, as it will depend on the individual risk factors and susceptibilities that<br />may be present at any time in any given patient.<br />Medicinal products that may prolong QTc interval, including vardenafil, are best avoided in<br />patients with relevant risk factors, for example, hypokalaemia, congenital QT prolongation,<br />concomitant administration of antiarrhythmic medicinal products in Class IA (e.g. quinidine,<br />procainamide), or Class III (e.g. amiodarone, sotalol).<br />Effect on vision<br />Visual defects and cases of non-arteritic ischemic optic neuropathy (NAION) have been<br />reported in connection with the intake of Vardenafil and other PDE5 inhibitors. Analyses of<br />observational data suggest an increased risk of acute NAION in men with erectile dysfunction<br />following exposure to PDE5 inhibitors such as vardenafil, tadalafil and sildenafil (see section<br />4.8). As this may be relevant for all patients exposed to vardenafil the patient should be<br />advised that in the case of sudden visual defect, he should stop taking Vardenafil<br />orodispersible tablets and consult immediately a physician (see section 4.3).<br />Effect on bleeding<br />In vitro studies with human platelets indicate that vardenafil has no antiaggregatory effect on<br />its own, but at high (super- therapeutic) concentrations vardenafil potentiates the<br />antiaggregatory effect of the nitric oxide donor sodium nitroprusside. In humans, vardenafil<br />had no effect on bleeding time alone or in combination with acetylsalicylic acid (see section<br />4.5). There is no safety information available on the administration of vardenafil to patients<br />with bleeding disorders or active peptic ulceration. Therefore vardenafil should be<br />administered to these patients only after careful benefit-risk assessment.<br />Aspartame<br />Devarin ODT contains aspartame, a source of phenylalanine which may be harmful for people<br />with phenylketonuria.<br />Lactose monohydrate<br />Devarin ODT contains lactose monohydrate. Patients with rare hereditary problems of galactose<br />intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this&nbsp;medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of other medicinal products on vardenafil<br />In vitro studies<br />Vardenafil is metabolised predominantly by hepatic enzymes via cytochrome P450 (CYP)<br />isoform 3A4, with some contribution from CYP3A5 and CYP2C isoforms. Therefore,<br />inhibitors of these isoenzymes reduce vardenafil clearance.<br />In vivo studies<br />Co-administration of the HIV protease inhibitor indinavir (800 mg three times a day), a potent<br />CYP3A4 inhibitor, with vardenafil (10 mg film-coated tablets) resulted in a 16-fold increase<br />in vardenafil AUC and a 7-fold increase in vardenafil Cmax. At 24 hours, the plasma levels of<br />vardenafil had fallen to approximately 4% of the maximum vardenafil plasma level (Cmax).<br />Co-administration of vardenafil with ritonavir (600 mg twice daily) resulted in a 13-fold<br />increase in vardenafil Cmax and a 49-fold increase in vardenafil AUC0-24 when coadministered<br />with vardenafil 5 mg. The interaction is a consequence of blocking hepatic<br />metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits<br />CYP2C9.<br />Ritonavir significantly prolonged the half-life of vardenafil to 25.7 hours (see section 4.3).<br />Co-administration of ketoconazole (200 mg), a potent CYP3A4 inhibitor, with vardenafil (5<br />mg) resulted in a 10-fold increase in vardenafil AUC and a 4-fold increase in vardenafil Cmax<br />(see section 4.4).<br />Although specific interaction studies have not been conducted, the concomitant use of other<br />potent CYP3A4 inhibitors (such as itraconazole) can be expected to produce vardenafil plasma<br />levels comparable to those produced by ketoconazole. Concomitant use of vardenafil with<br />potent CYP3A4 inhibitors such as itraconazole and ketoconazole (oral use) should be avoided<br />(see sections 4.3 and 4.4). In men older than 75 years the concomitant use of vardenafil with<br />itraconazole or ketoconazole is contraindicated (see section 4.3).<br />Co-administration of erythromycin (500 mg three times a day), a CYP3A4 inhibitor, with<br />vardenafil (5 mg) resulted in a 4- fold increase in vardenafil AUC and a 3-fold increase in<br />Cmax. Although a specific interaction study has not been conducted, the co-administration of<br />clarithromycin can be expected to result in similar effects on vardenafil AUC and Cmax.<br />When used in combination with a moderate CYP3A4 inhibitor such as erythromycin or<br />clarithromycin, vardenafil dose adjustment might be necessary (see sections 4.2 and 4.4).<br />Cimetidine (400 mg twice daily), a non-specific cytochrome P450 inhibitor, had no effect on<br />vardenafil AUC and Cmax when co-administered with vardenafil (20 mg) to healthy<br />volunteers.<br />Grapefruit juice being a weak inhibitor of CYP3A4 gut wall metabolism, may give rise to<br />modest increases in plasma levels of vardenafil (see section 4.4).<br />The pharmacokinetics of vardenafil (20 mg) was not affected by co-administration with the<br />H2-antagonist ranitidine (150 mg twice daily), digoxin, warfarin, glibenclamide, alcohol<br />(mean maximum blood alcohol level of 73 mg/dl) or single doses of antacid (magnesium<br />hydroxide/aluminium hydroxide).<br />Although specific interaction studies were not conducted for all medicinal products,<br />population pharmacokinetic analysis showed no effect on vardenafil pharmacokinetics of the<br />following concomitant medicinal products: acetylsalicylic acid, ACE-inhibitors, beta-blockers,<br />weak CYP3A4 inhibitors, diuretics and medicinal products for the treatment of diabetes<br />(sulfonylureas and metformin).<br />Effects of vardenafil on other medicinal products<br />There are no data on the interaction of vardenafil and non-specific phosphodiesterase<br />inhibitors such as theophylline or dipyridamole.<br />In vivo studies<br />No potentiation of the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) was<br />observed when vardenafil (10 mg) was given at varying time intervals (1 h to 24 h) prior to<br />the dose of nitroglycerin in a study in 18 healthy male subjects. Vardenafil 20 mg film-coated<br />tablets potentiated the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg)<br />taken 1 and 4 hours after vardenafil administration to healthy middle aged subjects. No effect<br />on blood pressure was observed when nitroglycerin was taken 24 hours after administration of<br />a single dose of vardenafil 20 mg film- coated tablets. However, there is no information on the<br />possible potentiation of the hypotensive effects of nitrates by vardenafil in patients, and<br />concomitant use of vardenafil orodispersible tablets and nitrates is therefore contraindicated<br />(see section 4.3).<br />Nicorandil is a hybrid of potassium channel opener and nitrate. Due to the nitrate component it<br />has the potential to have serious interaction with vardenafil.<br />Since alpha-blocker monotherapy can cause marked lowering of blood pressure, especially<br />postural hypotension and syncope, interaction studies were conducted with vardenafil. In two<br />interaction studies with healthy normotensive volunteers after forced titration of the alphablockers<br />tamsulosin or terazosin to high doses, hypotension (in some cases symptomatic) was<br />reported in a significant number of subjects after co-administration of vardenafil. Among<br />subjects treated with terazosin, hypotension was observed more frequently when vardenafil<br />and terazosin were given simultaneously than when the dosing was separated by a time<br />interval of 6 hours.<br />Based on the results of interaction studies conducted with vardenafil in patients with benign<br />prostatic hyperplasia (BPH) on stable tamsulosin, terazosin or alfuzosin therapy:<br />&bull; When vardenafil (film-coated tablets) was given at doses of 5, 10 or 20 mg on a<br />background of stable therapy with tamsulosin, there was no symptomatic reduction in blood<br />pressure, although 3/21 tamsulosin treated subjects exhibited transient standing systolic blood<br />pressures of less than 85 mmHg.<br />&bull; When vardenafil 5 mg (film-coated tablets) was given simultaneously with terazosin 5<br />or 10 mg, one of 21 patients experienced symptomatic postural hypotension. Hypotension was<br />not observed when vardenafil 5 mg and terazosin administration was separated by 6 hours.<br />&bull; When vardenafil (film-coated tablets) was given at doses of 5 or 10 mg on a<br />background of stable therapy with alfuzosin, compared to placebo, there was no symptomatic<br />reduction in blood pressure.<br />Therefore, concomitant treatment should be initiated only if the patient is stable on his alphablocker<br />therapy. In those patients who are stable on alpha-blocker therapy, vardenafil should<br />be initiated at the lowest recommended starting dose of 5mg. Vardenafil orodispersible tablets<br />may be administered at any time with tamsulosin or alfuzosin. With other alpha-blockers a<br />time separation of dosing should be considered when vardenafil is prescribed concomitantly<br />(see section 4.4).<br />Vardenafil 10 mg orodispersible tablets should not be taken as starting dose in patients treated<br />with alpha- blockers (see section 4.4).<br />No significant interactions were shown when warfarin (25 mg), which is metabolised by<br />CYP2C9, or digoxin (0.375 mg) was co-administered with vardenafil (20 mg film-coated<br />tablets). The relative bioavailability of glibenclamide (3.5 mg) was not affected when coadministered<br />with vardenafil (20 mg). In a specific study, where vardenafil (20 mg) was coadministered<br />with slow release nifedipine (30 mg or 60 mg) in hypertensive patients, there<br />was an additional reduction on supine systolic blood pressure of 6 mmHg and supine diastolic<br />blood pressure of 5 mmHg accompanied with an increase in heart rate of 4 bpm.<br />When vardenafil (20 mg film-coated tablets) and alcohol (mean maximum blood alcohol level<br />of 73 mg/dl) were taken together, vardenafil did not potentiate the effects of alcohol on blood<br />pressure and heart rate and the pharmacokinetics of vardenafil were not altered.<br />Vardenafil (10 mg) did not potentiate the increase in bleeding time caused by acetylsalicylic<br />acid (2 x 81 mg). Riociguat<br />Preclinical studies showed additive systemic blood pressure lowering effect when PDE5<br />inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to<br />augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable<br />clinical effect of the combination in the population studied. Concomitant use of riociguat with<br />PDE5 inhibitors, including vardenafil, is contraindicated (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vardenafil orodispersible tablets are not indicated for use by women. There are no studies of<br />vardenafil in pregnant women. There are no fertility data available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.<br />As dizziness and abnormal vision have been reported in clinical trials with vardenafil, patients<br />should be aware of how they react to vardenafil orodispersible tablets, before driving or<br />operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The adverse reactions reported with vardenafil film-coated tablets or vardenafil 10 mg<br />orodispersible tablets in clinical trials were generally transient and mild to moderate in nature.<br />The most commonly reported adverse drug reaction occurring in &ge; 10% of patients is<br />headache.<br />Tabulated list of adverse reactions<br />Adverse reactions are listed according to the MedDRA frequency convention: very common<br />(&ge;1/10), common (&ge;1/100 to<br />&lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and not known (can not<br />be estimated from available data).<br />Within each frequency grouping, adverse reactions are presented in order of decreasing<br />seriousness. The following adverse reactions have been reported:<br />System Organ Very common Common Uncommon Rare Not known<br />Class (&ge;1/10) (&ge;1/100 to (&ge;1/1,000 to (&ge;1/10,000 to (can not be<br />&lt;1/10) &lt;1/100) &lt;1/1,000) estimated from the<br />available data)<br />Infection and<br />infestations<br />Conjunctivitis<br />Immune system<br />disorders<br />Allergic oedema<br />and angioedema<br />Allergic reaction<br />Psychiatric<br />disorders<br />Sleep disorder Anxiety<br />Nervous system<br />disorders<br />Headache Dizziness Somnolence<br />Paraesthesia and<br />dysaesthesia<br />Syncope<br />Seizure<br />Amnesia<br />Eye disorders Visual disturbance<br />Ocular hyperaemia<br />Increase in<br />intraocular pressure<br />Lacrimation<br />increased<br />Non-arteritic<br />anterior ischemic<br />optic neuropathy<br />Visual defects<br />Visual colour<br />distortions<br />Eye pain and eye<br />discomfort<br />Photophobia<br />Ear and<br />labyrinth<br />disorders<br />Tinnitus Vertigo Sudden deafn<br />Cardiac<br />disorders<br />Palpitation<br />Tachycardia<br />Myocardial<br />infarction<br />Ventricular tachyarrhythmias<br />Angina pectoris<br />Vascular<br />disorders<br />Flushing Hypotension<br />Hypertension<br />Respiratory,<br />thoracic and<br />mediastinal<br />disorders<br />Nasal<br />congestion<br />Dyspnoea<br />Sinus congestion<br />Epistaxis<br />Gastrointestinal<br />disorders<br />Dyspepsia Gastrooesophageal<br />reflux<br />disease<br />Gastritis<br />Gastrointestinal<br />and abdominal<br />pain<br />Diarrhoea<br />Vomiting Nausea<br />Dry mouth<br />Hepatobiliary<br />disorders<br />Increase in<br />transaminases<br />Increase in gammaglutamyl<br />Skin and<br />subcutaneous<br />tissue disorders<br />Erythema Rash Photosensitivity<br />reaction<br />Musculoskeletal<br />and connective<br />tissue disorders<br />Back pain<br />Increase in<br />creatine<br />phosphokinase<br />Myalgia Increased<br />muscle<br />tone and cramping<br />Renal and<br />urinary<br />disorders<br />Haematuria<br />Reproductive<br />system and<br />breast disorders<br />Increase in<br />erection<br />Priapism Penile Haemo<br />Haematosperm<br />General<br />disorders and<br />Feeling unwell Chest pain<br />Description of selected adverse reactions<br />Penile haemorrhage, haematospermia and haematuria have been reported in clinical trials and<br />spontaneous post- marketing data with the use of all PDE5 inhibitors, including vardenafil.<br />At a dose of 20 mg vardenafil film-coated tablets, elderly (&ge; 65 years old) patients had higher<br />frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than<br />younger patients (&lt; 65 years old). In general, the incidence of adverse reactions (especially<br />&ldquo;dizziness&rdquo;) has been shown to be slightly higher in patients with a history of hypertension.<br />Post-marketing observations<br />Vascular disorders<br />Serious cardiovascular reactions, including cerebrovascular haemorrhage, sudden cardiac<br />death, transient ischaemic attack, unstable angina and ventricular arrhythmia have been<br />reported post-marketing in temporal association with another medicinal product in this class.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important.<br />It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions via:<br />To report any side effect(s):<br />&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In single dose volunteer studies, doses up to and including 80 mg vardenafil (film-coated<br />tablets) per day were tolerated without exhibiting serious adverse reactions.<br />When vardenafil was administered in higher doses and more frequently than the recommended<br />dose regimen (40 mg film-coated tablets twice daily) cases of severe back pain have been<br />administration<br />site conditions<br />reported. This was not associated with any muscle or neurological toxicity.<br />In cases of overdose, standard supportive measures should be adopted as required. Renal<br />dialysis is not expected to accelerate clearance, as vardenafil is highly bound to plasma<br />proteins and not significantly eliminated in the urine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction, ATC code:<br />G04BE09.<br />Vardenafil is an oral therapy for the improvement of erectile function in men with erectile<br />dysfunction. In the natural setting, i.e. with sexual stimulation it restores impaired erectile<br />function by increasing blood flow to the penis.<br />Penile erection is a haemodynamic process. During sexual stimulation, nitric oxide is released.<br />It activates the enzyme guanylate cyclase, resulting in an increased level of cyclic guanosine<br />monophosphate (cGMP) in the corpus cavernosum. This in turn results in smooth muscle<br />relaxation, allowing increased inflow of blood into the penis. The level of cGMP is regulated<br />by the rate of synthesis via guanylate cyclase and by the rate of degradation via cGMP<br />hydrolysing phosphodiesterases (PDEs).<br />Vardenafil is a potent and selective inhibitor of the cGMP specific phosphodiesterase type 5<br />(PDE5), the most prominent PDE in the human corpus cavernosum. Vardenafil potently<br />enhances the effect of endogenous nitric oxide in the corpus cavernosum by inhibiting PDE5.<br />When nitric oxide is released in response to sexual stimulation, inhibition of PDE5 by<br />vardenafil results in increased corpus cavernosum levels of cGMP. Sexual stimulation is<br />therefore required for vardenafil to produce its beneficial therapeutic effects.<br />In vitro studies have shown that vardenafil is more potent on PDE5 than on other known<br />phosphodiesterases (&gt;15-fold relative to PDE6, &gt;130-fold relative to PDE1, &gt;300-fold relative<br />to PDE11, and &gt;1000-fold relative to PDE2, PDE3, PDE4, PDE7, PDE8, PDE9 and PDE10).<br />In a penile plesthysmography (RigiScan) study, vardenafil 20 mg produced erections<br />considered sufficient for penetration (60% rigidity by RigiScan) in some men as early as 15<br />minutes after dosing. The overall response of these subjects to vardenafil became statistically<br />significant, compared to placebo, 25 minutes after dosing.<br />Vardenafil causes mild and transient decreases in blood pressure which, in the majority of the<br />cases, do not translate into clinical effects. The mean maximum decreases in supine systolic<br />blood pressure following 20 mg and 40 mg vardenafil were &ndash; 6.9 mmHg under 20 mg and &ndash;<br />4.3 mmHg under 40 mg of vardenafil, when compared to placebo.<br />These effects are consistent with the vasodilatory effects of PDE5-inhibitors and are probably<br />due to increased cGMP levels in vascular smooth muscle cells. Single and multiple oral doses<br />of vardenafil up to 40 mg produced no clinically relevant changes in the ECGs of normal male<br />volunteers.<br />A single dose, double blind, crossover, randomised trial in 59 healthy males compared the<br />effects on the QT interval of vardenafil (10 mg and 80 mg), sildenafil (50 mg and 400 mg)<br />and placebo. Moxifloxacin (400 mg) was included as an active internal control. Effects on the<br />QT interval were measured one hour post-dose (average tmax for vardenafil). The primary<br />objective of this study was to rule out a greater than 10 msec effect (i.e. to demonstrate lack of<br />effect) of a single 80 mg oral dose of vardenafil on QTc interval compared to placebo, as<br />measured by the change in Fridericia&#39;s correction formula (QTcF=QT/RR1/3) from baseline at<br />the 1 hour post-dose time point. The vardenafil results showed an increase in QTc (Fridericia)<br />of 8 msec (90% CI: 6-9) and 10 msec (90% CI: 8-11) at 10 and 80 mg doses compared to<br />placebo and<br />an increase in QTci of 4 msec (90% CI: 3-6) and 6 msec (90% CI: 4-7) at 10 and 80 mg doses<br />compared to placebo, at one hour post-dose. At tmax, only the mean change in QTcF for<br />vardenafil 80 mg was out of the study established limit (mean 10 msec, 90% CI 8-11). When<br />using the individual correction formulae, none of the values were out of the limit.<br />In a separate post-marketing study of 44 healthy volunteers, single doses of 10 mg vardenafil<br />or 50 mg sildenafil were co-administered concomitantly with 400 mg gatifloxacin, a drug with<br />comparable QT effect. Both vardenafil and sildenafil showed an increase of Fridericia QTc<br />effect of 4 msec (vardenafil) and 5 msec (sildenafil) when compared to either drug alone. The<br />actual clinical impact of these QT changes is unknown.<br />Further information on clinical trials with vardenafil 10 mg orodispersible tablets<br />Efficacy and safety of vardenafil 10 mg orodispersible tablets were separately demonstrated in<br />a broad population in two studies including 701 randomized erectile dysfunction patients who<br />were treated up to 12 weeks. The distribution of patients in the predefined subgroups was<br />covering elderly patients (51%), patients with history of diabetes mellitus (29%), dyslipidemia<br />(39%) and hypertension (40%).<br />In pooled data from the two vardenafil 10 mg orodispersible tablets trials, IIEF-EF domain<br />scores were significantly higher with vardenafil 10 mg orodispersible tablet versus placebo.<br />A percentage of 71% of all sexual attempts reported in the clinical trials had successful<br />penetration compared to 44% of all attempts in the placebo group. These results were also<br />reflected in subgroups, in elderly patients (65%), in patients with history of diabetes mellitus<br />(63%), patients with history of dyslipidemia (66%) and hypertension (70%) of all sexual<br />attempts reported had successful penetration.<br />About 63% of all reported sexual attempts with vardenafil 10 mg orodispersible tablets were<br />successful in terms of erection maintenance compared to about 26% of all placebo-controlled<br />sexual attempts. In the predefined subgroups 57% (elderly patients), 56% (patients with<br />history of diabetes mellitus), 59% (patients with history of dyslipidemia) and 60% (patients<br />with history of hypertension) of all reported attempts with vardenafil 10 mg orodispersible<br />tablets were successful in terms of maintenance of erection.<br />Further information on clinical trials<br />In clinical trials vardenafil was administered to over 17,000 men with erectile dysfunction<br />(ED) aged 18-89 years, many of whom had multiple co-morbid conditions. Over 2,500<br />patients were treated with vardenafil for 6 months or longer. Of these, 900 patients have been<br />treated for one year or longer.<br />The following patient groups were represented: elderly (22%), patients with hypertension<br />(35%), diabetes mellitus (29%), ischaemic heart disease and other cardiovascular diseases<br />(7%), chronic pulmonary disease (5%), hyperlipidaemia (22%), depression (5%), radical<br />prostatectomy (9%). The following groups were not well represented in clinical trials: elderly<br />(&gt;75 years, 2.4%), and patients with certain cardiovascular conditions (see section 4.3). No<br />clinical trials in CNS diseases (except spinal cord injury), patients with severe renal or hepatic<br />impairment, pelvic surgery (except nerve- sparing prostatectomy) or trauma or radiotherapy<br />and hypoactive sexual desire or penile anatomic deformities have<br />been performed.<br />Across the pivotal trials, treatment with vardenafil (film-coated tablets) resulted in an<br />improvement of erectile function compared to placebo. In the small number of patients who<br />attempted intercourse up to four to five hours after dosing the success rate for penetration and<br />maintenance of erection was consistently greater than placebo.<br />In fixed dose studies (film-coated tablets) in a broad population of men with erectile<br />dysfunction, 68% (5 mg), 76% (10 mg) and 80% (20 mg) of patients experienced successful<br />penetrations (SEP 2) compared to 49% on placebo over a three month study period. The<br />ability to maintain the erection (SEP 3) in this broad ED population was given as 53% (5 mg),<br />63% (10 mg) and 65% (20 mg) compared to 29% on placebo.<br />In pooled data from the major efficacy trials, the proportion of patients experiencing<br />successful penetration on vardenafil were as follows: psychogenic erectile dysfunction (77-<br />87%), mixed erectile dysfunction (69-83%), organic erectile dysfunction (64-75%), elderly<br />(52-75%), ischaemic heart disease (70-73%), hyperlipidaemia (62-73%), chronic pulmonary<br />disease (74-78%), depression (59-69%), and patients concomitantly treated with<br />antihypertensives (62-73%).<br />In a clinical trial in patients with diabetes mellitus, vardenafil significantly improved the<br />erectile function domain score, the ability to obtain and maintain an erection long enough for<br />successful intercourse and penile rigidity compared to placebo at vardenafil doses of 10 mg<br />and 20 mg. The response rates for the ability to obtain and maintain an erection was 61% and<br />49% on 10 mg and 64% and 54% on 20 mg vardenafil compared to 36% and 23% on placebo<br />for patients who completed three months treatment.<br />In a clinical trial in post-prostatectomy patients, vardenafil significantly improved the erectile<br />function domain score, the ability to obtain and maintain an erection long enough for<br />successful intercourse and penile rigidity compared to placebo at vardenafil doses of 10 mg<br />and 20 mg. The response rates for the ability to obtain and maintain an erection was 47% and<br />37% on 10 mg and 48% and 34% on 20 mg vardenafil compared to 22% and 10% on placebo<br />for patients who completed three months treatment.<br />In a flexible-dose clinical trial in patients with Spinal Cord Injury, vardenafil significantly<br />improved the erectile function domain score, the ability to obtain and maintain an erection<br />long enough for successful intercourse and penile rigidity compared to placebo. The number<br />of patients who returned to a normal IIEF domain score (&gt;26) were 53% on vardenafil<br />compared to 9% on placebo. The response rates for the ability to obtain and maintain an<br />erection were 76% and 59% on vardenafil compared to 41% and 22% on placebo for patients<br />who completed three months treatment which were clinically and statistically significant<br />(p&lt;0.001).<br />The safety and efficacy of vardenafil was maintained in long-term studies. Paediatric<br />population<br />The European Medicines Agency has waived the obligation to submit the results of studies in<br />all subsets of the paediatric population in the treatment of the erectile dysfunction. See section<br />4.2 for information on paediatric use</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bioequivalence studies have shown that vardenafil 10 mg orodispersible tablet is not<br />bioequivalent to vardenafil 10 mg film-coated tablets. Therefore the orodispersible formulation<br />should not be used as an equivalent to vardenafil 10 mg film-coated tablets.<br />Absorption<br />In vardenafil film-coated tablets, vardenafil is rapidly absorbed with maximum observed<br />plasma concentrations reached in some men as early as 15 minutes after oral administration.<br />However, 90% of the time, maximum plasma concentrations are reached within 30 to 120<br />minutes (median 60 minutes) of oral dosing in the fasted state. The mean absolute oral<br />bioavailability is 15%. After oral dosing of vardenafil AUC and Cmax increase almost dose<br />proportionally over the recommended dose range (5-20 mg).<br />When vardenafil film-coated tablets are taken with a high fat meal (containing 57% fat), the<br />rate of absorption is reduced, with an increase in the median tmax of 1 hour and a mean<br />reduction in Cmax of 20%. Vardenafil AUC is not affected. After a meal containing 30% fat,<br />the rate and extent of absorption of vardenafil (tmax, Cmax and AUC) are unchanged<br />compared to administration under fasting conditions.<br />Vardenafil is rapidly absorbed after administration of vardenafil 10 mg orodispersible tablets<br />without water. The median time to reach Cmax varied between 45 to 90 minutes and was<br />similar or slightly delayed (by 8 to 45 min) compared to the film- coated tablets. Mean<br />vardenafil AUC was increased by 21 to 29% (middle aged and elderly ED patients) or 44%<br />(young healthy subjects) with 10 mg orodispersible tablets compared to film-coated tablets as<br />a result of local oral absorption of a small amount of drug in the oral cavity. There was no<br />consistent difference in mean Cmax between orodispersible tablets and film-coated tablets.<br />In subjects taking vardenafil 10 mg orodispersible tablets with a high fat meal no effect on<br />vardenafil AUC and tmax was observed, while vardenafil Cmax was reduced by 35% in the<br />fed condition. Based on these results vardenafil 10 mg orodispersible tablets can be taken with<br />or without food.<br />If vardenafil 10 mg orodispersible tablets are taken with water, the AUC is reduced by 29%,<br />Cmax remains unchanged and median tmax is shortened by 60 minutes compared to intake<br />without water. vardenafil 10 mg orodispersible tablets must be taken without liquid.<br />Distribution<br />The mean steady state volume of distribution for vardenafil is 208 l, indicating distribution<br />into the tissues.<br />Vardenafil and its major circulating metabolite (M1) are highly bound to plasma proteins<br />(approximately 95% for vardenafil or M1). For vardenafil as well as M1, protein binding is<br />independent of total drug concentrations.<br />Based on measurements of vardenafil in semen of healthy subjects 90 minutes after dosing,<br />not more than 0.00012% of the administered dose may appear in the semen of patients.<br />Biotransformation<br />Vardenafil in film-coated tablets is metabolised predominantly by hepatic metabolism via<br />cytochrome P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C<br />isoforms.<br />In humans the one major circulating metabolite (M1) results from desethylation of vardenafil<br />and is subject to further metabolism with a plasma elimination half-life of approximately 4<br />hours. Parts of M1 are in the form of the glucuronide in systemic circulation. Metabolite M1<br />shows a phosphodiesterase selectivity profile similar to vardenafil and an in vitro potency for<br />phosphodiesterase type 5 of approximately 28% compared to vardenafil, resulting in an<br />efficacy contribution of about 7%.<br />The mean terminal half-life of vardenafil in patients receiving vardenafil 10 mg orodispersible<br />tablets ranged between 4 &ndash; 6 hours. The elimination half-life of the metabolite M1 is between<br />3 to 5 hours, similar to parent drug.<br />Elimination<br />The total body clearance of vardenafil is 56 l/h with a resultant terminal half-life of<br />approximately 4-5 hours. After oral administration, vardenafil is excreted as metabolites<br />predominantly in the faeces (approximately 91-95% of the administered dose) and to a lesser<br />extent in the urine (approximately 2-6% of the administered dose).<br />Pharmacokinetics in special patient groups<br />Elderly<br />Hepatic clearance of vardenafil in healthy elderly volunteers (65 years and over) was reduced<br />as compared to healthy younger volunteers (18-45 years). On average elderly males taking<br />vardenafil film-coated tablets had a 52% higher AUC, and a 34% higher Cmax than younger<br />males (see section 4.2).<br />Vardenafil AUC and Cmax in elderly patients (65 years or over) taking vardenafil<br />orodispersible tablets were increased by 31 to 39% and 16 to 21%, respectively, in comparison<br />to patients aged 45 years and below. Vardenafil was not found to accumulate in the plasma in<br />patients aged 45 years and below or 65 years or over following once-daily dosing of vardenafil<br />10 mg orodispersible tablets over ten days.<br />Renal impairment<br />In volunteers with mild to moderate renal impairment (creatinine clearance 30-80 ml/min), the<br />pharmacokinetics of vardenafil were similar to that of a normal renal function control group.<br />In volunteers with severe renal impairment (creatinine clearance &lt;30 ml/min) the mean AUC<br />was increased by 21% and the mean Cmax decreased by 23%, compared to volunteers with<br />no renal impairment. No statistically significant correlation was observed between creatinine<br />clearance and vardenafil exposure (AUC and Cmax) (see section 4.2). Vardenafil<br />pharmacokinetics has not been studied in patients requiring dialysis (see section 4.3).<br />Hepatic impairment<br />In patients with mild to moderate hepatic impairment (Child-Pugh A and B), the clearance of<br />vardenafil was reduced in proportion to the degree of hepatic impairment. In patients with<br />mild hepatic impairment (Child-Pugh A), the mean AUC and Cmax increased by 17% and<br />22% respectively, compared to healthy control subjects. In patients with moderate impairment<br />(Child-Pugh B), the mean AUC and Cmax increased by 160% and 133% respectively,<br />compared to healthy control subjects (see section 4.2). The pharmacokinetics of vardenafil in<br />patients with severely impaired hepatic function (Child-Pugh C) has not been studied (see<br />section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to<br />reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate<br />Calcium silicate<br />Hydroxypropyl cellulose<br />Crospovidone<br />Aspartame<br />Mint flavor<br />Aniseed flavor<br />Colloidal silicon dioxide<br />Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Devarin ODT: PP/Aluminium foil blisters in cartons of 4 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LABORATORIOS CINFA, S.A.
Olaz-Chipi,10. Polígono Industrial Areta,
31620 Huarte-Pamplona (Navarra) – Spain
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>